Virax Biolabs Shares Rise Sharply on Distribution Agreement

Dow Jones10-24
 

By Stephen Nakrosis

 

U.S.-listed shares of Virax Biolabs rose sharply in heavy volume after the British biotechnology company said it reached an agreement with distributor Europa Biosite to commercialize a portfolio of research products in the U.K. and Ireland.

In afternoon trading Wednesday, Virax shares were up 62% at $2.73. Volume in the session topped 80 million shares, above the stock's 65-day average volume of about 4.5 million.

ImmuneSelect is a suite of research products for assessing adaptive immunity.

 

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

 

(END) Dow Jones Newswires

October 23, 2024 14:18 ET (18:18 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment